Literature DB >> 24202110

[Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].

K Doppler1, C Sommer.   

Abstract

Voltage-gated sodium channels are essential for electrogenesis in excitable cells. The isoform Nav1.7 is primarily expressed in nociceptors. Mutations of the SCN9A gene, which codes for the α-subunit of Nav1.7, are the cause of primary erythromelalgia and paroxysmal extreme pain disorder, two rare neuropathic pain conditions. Recent studies have shown that mutations in the SCN9A gene are the cause of a subgroup of idiopathic small fiber neuropathies and that polymorphisms of SCN9A are associated with an increase in susceptibility to pain. These findings not only contribute to the understanding of the pathophysiology of neuropathic pain but also offer targets for a more specific pain therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24202110     DOI: 10.1007/s00115-012-3621-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  30 in total

1.  Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.

Authors:  Howard Bregman; Loren Berry; John L Buchanan; April Chen; Bingfan Du; Elma Feric; Markus Hierl; Liyue Huang; David Immke; Brett Janosky; Danielle Johnson; Xingwen Li; Joseph Ligutti; Dong Liu; Annika Malmberg; David Matson; Jeff McDermott; Peter Miu; Hanh Nho Nguyen; Vinod F Patel; Daniel Waldon; Ben Wilenkin; Xiao Mei Zheng; Anruo Zou; Stefan I McDonough; Erin F DiMauro
Journal:  J Med Chem       Date:  2011-06-02       Impact factor: 7.446

2.  A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia.

Authors:  Gilberto Vargas-Alarcon; Edith Alvarez-Leon; Jose-Manuel Fragoso; Angelica Vargas; Aline Martinez; Maite Vallejo; Manuel Martinez-Lavin
Journal:  BMC Musculoskelet Disord       Date:  2012-02-20       Impact factor: 2.362

3.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.

Authors:  G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé
Journal:  Eur J Neurol       Date:  2010-07       Impact factor: 6.089

4.  Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.

Authors:  Nagasree Chakka; Howie Bregman; Bingfan Du; Hanh Nho Nguyen; John L Buchanan; Elma Feric; Joseph Ligutti; Dong Liu; Jeff S McDermott; Anruo Zou; Stefan I McDonough; Erin F Dimauro
Journal:  Bioorg Med Chem Lett       Date:  2012-01-18       Impact factor: 2.823

5.  Paroxysmal extreme pain disorder.

Authors:  J Beck; P Cramp; J Noden
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

6.  Comparison of different modalities for detection of small fiber neuropathy.

Authors:  K Tobin; M J Giuliani; D Lacomis
Journal:  Clin Neurophysiol       Date:  1999-11       Impact factor: 3.708

7.  Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.

Authors:  Theodore R Cummins; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

8.  Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.

Authors:  Scott B Hoyt; Clare London; Hyun Ok; Edward Gonzalez; Joseph L Duffy; Catherine Abbadie; Brian Dean; John P Felix; Maria L Garcia; Nina Jochnowitz; Bindhu V Karanam; Xiaohua Li; Kathryn A Lyons; Erin McGowan; D Euan Macintyre; William J Martin; Birgit T Priest; McHardy M Smith; Richard Tschirret-Guth; Vivien A Warren; Brande S Williams; Gregory J Kaczorowski; William H Parsons
Journal:  Bioorg Med Chem Lett       Date:  2007-09-11       Impact factor: 2.823

9.  Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.

Authors:  J Natkunarajah; D Atherton; F Elmslie; S Mansour; P Mortimer
Journal:  Clin Exp Dermatol       Date:  2009-06-22       Impact factor: 3.470

10.  A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.

Authors:  Tanya Z Fischer; Elaine S Gilmore; Mark Estacion; Emmanuella Eastman; Sean Taylor; Michel Melanson; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

View more
  2 in total

1.  MicroRNA-182 Alleviates Neuropathic Pain by Regulating Nav1.7 Following Spared Nerve Injury in Rats.

Authors:  Weihua Cai; Qingzan Zhao; Jinping Shao; Jingjing Zhang; Lei Li; Xiuhua Ren; Songxue Su; Qian Bai; Ming Li; Xuemei Chen; Jian Wang; Jing Cao; Weidong Zang
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

Review 2.  Understanding the Psychological, Physiological, and Genetic Factors Affecting Precision Pain Medicine: A Narrative Review.

Authors:  Andrea Chadwick; Andrew Frazier; Talal W Khan; Erin Young
Journal:  J Pain Res       Date:  2021-10-08       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.